Back to Neurology
Neurologyv2014Evidence-Based

Embolic Stroke of Undetermined Source (ESUS) Criteria

Diagnostic criteria for identifying embolic stroke of undetermined source after comprehensive evaluation excluding other specific stroke etiologies.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
esus diagnosis
—Points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Embolic Stroke of Undetermined Source (ESUS) Criteria is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within neurology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

ESUS diagnosis requires ALL criteria to be met: (1) Non-lacunar stroke on imaging, (2) No significant atherosclerosis (≥50% stenosis), (3) No major cardioembolic source, (4) No other specific stroke cause, AND adequate diagnostic evaluation completed.

Clinical Pearls & Practice Notes

  • ESUS represents 15-25% of all ischemic strokes, with higher prevalence in younger patients.
  • Lacunar stroke is defined as subcortical infarct ≤1.5 cm (≤2.0 cm on MRI diffusion images) in small penetrating artery distribution.
  • Major cardioembolic sources include: permanent/paroxysmal atrial fibrillation, sustained atrial flutter, intracardiac thrombus, prosthetic cardiac valve, atrial myxoma, mitral stenosis, recent MI (<4 weeks), LVEF <30%, valvular vegetations, infective endocarditis.
  • Minimum diagnostic evaluation requires: 12-lead ECG, ≥24-hour cardiac monitoring with automated rhythm detection, echocardiography (TTE and/or TEE), vascular imaging of both extracranial and intracranial arteries.
  • Vascular imaging methods include catheter angiography, MR/CT angiography, or cervical duplex plus transcranial Doppler ultrasonography.
  • Other specific causes to exclude: arteritis, dissection, migraine/vasospasm, drug misuse, genetic disorders, hypercoagulable states.
  • ESUS patients tend to be younger (mean age 65) with milder strokes (mean NIHSS 5) compared to other stroke subtypes.
  • Stroke recurrence rate in ESUS is approximately 4.5% per year, similar to cardioembolic stroke.
  • Extended cardiac monitoring (>24 hours) may detect paroxysmal atrial fibrillation in 5-15% of ESUS patients.
  • The term ESUS replaced 'cryptogenic stroke' to provide standardized criteria for clinical trials and research.
  • ESUS criteria enable enrollment in specific clinical trials investigating anticoagulation strategies.
  • Patients meeting ESUS criteria may benefit from extended cardiac monitoring, cardiac MRI, or genetic testing.
  • The diagnosis has implications for secondary stroke prevention strategies and treatment selection.
  • ESUS classification facilitates targeted research into stroke mechanisms and therapeutic interventions.
  • Regular reassessment may be needed as new diagnostic technologies become available.
  • The criteria should be applied only after completion of adequate diagnostic evaluation as defined.
  • ESUS diagnosis does not preclude investigation of rare or uncommon stroke etiologies when clinically indicated.

Evidence & Literature Citations

  1. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O'Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429-38. doi: 10.1016/S1474-4422(13)70310-7.
  2. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24(1):35-41.
  3. Ntaios G, Papavasileiou V, Milionis H, Makaritsis K, Manios E, Spengos K, et al. Embolic strokes of undetermined source in the Athens stroke registry: an outcome analysis. Stroke. 2015;46(8):2087-93. doi: 10.1161/STROKEAHA.115.009334.
  4. Perera KS, Vanassche T, Bosch J, Swaminathan B, Mundl H, Giruparajah M, et al. Embolic strokes of undetermined source: prevalence and patient features in the ESUS Global Registry. Int J Stroke. 2016;11(5):526-33. doi: 10.1177/1747493016641967.
  5. Diener HC, Bernstein R, Butcher K, Campbell B, Cloud G, Davalos A, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906-17. doi: 10.1056/NEJMoa1813959.

Score Interpretation Ranges

ESUS Diagnosis Confirmed – pts

Meets all ESUS criteria

ESUS Diagnosis Not Met – pts

Does not meet ESUS criteria

Inadequate Evaluation – pts

Insufficient diagnostic workup

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.